Seqens Group, an integrated leader in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates, today announced that it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass. Serving as one of the company’s global centers

Ajinomoto Co., Inc.today announced a license agreement with Exelixis, Inc. to develop AJICAP , its proprietary site-specific bioconjugation and Linker Technology of Ajinomoto Co., in the development of certain Exelixis Antibody-Drug Conjugate programs.Exelixis is a commercially successful Exelixis is a commercially successful

Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann